Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer

Anticancer Research

Volumn 28, Issue 4 B, 2008, Pages 2087-2092

  Tozawa, Katsuyuki ^a   Oshima, Tadayuki ^a   Kobayashi, Takehiko ^b   Yamamoto, Noriyasu ^a   Hayashi, Chizuko ^a   Matsumoto, Takayuki ^a   Miwa, Hiroto ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Division of Internal Medicine   (Japan)

Author keywords

Cddp resistant cell line; ERCC1; Gastric cancer; GST ; MKN45; Oxaliplatin

Indexed keywords

CISPLATIN; COLLAGEN GEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE; OXALIPLATIN;

ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; STOMACH CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; GLUTATHIONE S-TRANSFERASE PI; HUMANS; ORGANOPLATINUM COMPOUNDS; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 49049109075     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bamias A and Pavlidis N: Systemic chemotherapy in gastric cancer: Where do we stand today? Oncologist 3: 171-177, 1998.
2. Beer M, Cocconi G, Ceci G, Varini M and Cavalli F: A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19: 717-720, 1983.
3. Wils JA: Current status of chemotherapy for advanced gastric cancer. Anticancer Res 7: 755-759, 1987.
4. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R and Lagarde C: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533-536, 1980.
5. Hainsworth JD, Johnson DH and Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10: 912-922, 1992.
6. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K and Kurihara M: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 30A: 2091-2093, 1994.
7. Timmer-Bosscha H, Mulder NH and de Vries EG: Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 66: 227-238, 1992.
8. Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C and Dempke W: Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. Anticancer Res 25: 1147-1155, 2005.
9. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F and Reed E: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 273: 23419-23425, 1998.
10. Gately DP and Howell SB: Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176, 1993.
11. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1988.
12. Eastman A: Reevaluation of interaction of cis-dichloro (ethylenediamine)platinum(II) with DNA. Biochemistry 25: 3912-3915, 1986.
13. Zaniboni A and Meriggi F: The emerging role of oxaliplatin in the treatment of gastric cancer. J Chemother 17: 656-662, 2005.
14. Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y and Sekiguchi M: A molecular biological study of anti-tumor mechanisms of an anti-cancer agent oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother 57: 412-415, 2003.
15. Trojan J, Kim SZ, Engels K, Kriener S, Mitrou PS and Chow KU: In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer. Anticancer Drugs 16: 87-91, 2005.
16. Hong WS and Son YS: Biochemical characterization of cisplatin-resistance in MKN-45 human stomach adenocarcinoma cell line. Anticancer Res 16: 3031-3036, 1996.
17. Gibson UE, Heid CA and Williams PM: A novel method for real-time quantitative RT-PCR. Genome Res 6: 995-1001, 1996.
18. Heid CA, Stevens J, Livak KJ and Williams PM: Real-time quantitative PCR. Genome Res 6: 986-994, 1996.
19. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM and Becker DA: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18: 184-191, 1977.
20. Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist 10(Suppl 3): 49-58, 2005.
21. Cavanna L, Artioli F, Codignola C, Lazzaro A, Rizzi A, Gamboni A, Rota L, Rodino C, Boni F, Iop A and Zaniboni A: Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol 29: 371-375, 2006.
22. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331-344, 1998.
23. Galm O, Fabry U, Efferth T and Osieka R: Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression. Cancer Lett 187: 143-151, 2002.
24. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B and Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
25. Xu H, Choi SM, An CS, Min YD, Kim KC, Kim KJ and Choi CH: Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun 328: 618-622, 2005.
26. Fan KC, Huang YC and Li CH: Radioimmunoassay for plasma glutathione-S-transferase-pi and its clinical application in gastrointestinal cancer. Cancer 76: 1363-1367, 1995.
27. Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M and Sugimachi K: Expression of glutathione-S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 74: 1230-1236, 1994.
28. Mistry P, Kelland LR, Abel G, Sidhar S and Harrap KR: The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215-220, 1991.
29. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S and Pendyala L: In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48: 398-406, 2001.
30. Hector S, Nava ME, Clark K, Murphy M and Pendyala L: Characterization of a clonal isolate of an oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Cancer Lett 245: 195-204, 2007.
31. Arnould S, Hennebelle I, Canal P, Bugat R and Guichard S: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39: 112-119, 2003.
32. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K and Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855-1865, 1996.
33. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886, 1996.